FDA Clearance Tracker · P840064-S092
VISCOAT Ophthalmic Viscosurgical Device; DUOVISC Ophthalmic Viscoelastic System.
Last checked: Nov 20, 2026Latest source record: Aug 4, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Aug 4, 2026
Approved
Time to decision
158 days
Received Feb 27, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P840064-S092
- Device name
- VISCOAT Ophthalmic Viscosurgical Device; DUOVISC Ophthalmic Viscoelastic System.
- Applicant
- Alcon Laboratories
- Applicant location
- Fort Worth, TX
- Received
- Feb 27, 2026
- Decided
- Aug 4, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P840064
Device type
- Device type
- AID, SURGICAL, VISCOELASTIC (LZP)
- Device class
- Class III
- Regulation
- 21 CFR 886.4275
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
An alternate manufacturing site at Alcon Fort Worth Manufacturing located at 6201 South Freeway, Fort Worth, Texas to perform the semiautomatic assembly of filled OVD (PROVISC, VISCOAT, and DUOVISC) syringes and components into blister packs, and packaging.
Source documents
Other decisions for Alcon Laboratories
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K254052 · Decided Feb 13, 2026 · 58 days after receipt
Device type: Lenses, Soft Contact, Daily Wear (LPL) · Ophthalmology
K252682 · Decided Sep 24, 2025 · 30 days after receipt
Device type: Ophthalmic Femtosecond Laser (OOE) · Ophthalmology
K243896 · Decided Apr 28, 2025 · 131 days after receipt
Device type: Ophthalmic Femtosecond Laser (OOE) · Ophthalmology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.